FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	<b>OWNERSHIP</b>

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Brzeczko Albert W			<u>A</u>	2. Issuer Name and Ticker or Trading Symbol ACURA PHARMACEUTICALS, INC ACUR ]					(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  X Officer (give title Other (specify					
(Last) (First) (Middle) C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT SUITE 120			03	3. Date of Earliest Transaction (Month/Day/Year) 03/16/2022  4. If Amendment, Date of Original Filed (Month/Day/Year)					VP, Pharma Sciences - APT  5. Individual or Joint/Group Filing (Check Applicable						
(Street) PALATII			60067 (Zip)	4.	II AME	enament, L	Date (	or Originai File	ea (Montin/D	ay/Year)	Line	) <mark>X</mark> Form fi	led by One R	Reporting Perso	n
1. Title of Security (Instr. 3) 2. Transac Date			Transactio	2A. Deemed Execution Date,		quired, Disposed of, or Benefi  3. Transaction Code (Instr. 3, r) 8)  4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)		ed (A) or	5. Amour Securitie Beneficia Owned F	nt of 6. Or es Formally (D) (C) (I) (II)	. Ownership Form: Direct D) or Indirect I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
Table II - Derivat					Code V Amount (A) or Price Reported Transaction(s) (Instr. 3 and 4)					(Instr. 4)					
(e.g., )  1. Title of Derivative Conversion Date Execution Date, Security or Exercise (Month/Day/Year) if any		4. Trans Code	ansaction of I		6. Oate Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Unit <sup>(1)</sup>	\$0.01 <sup>(2)</sup>	03/16/2022		A		40,000		(3)	(3)	Common Stock	40,000	(4)	117,332	D	

## Explanation of Responses:

- 1. Awarded under the Acura Pharmaceuticals Inc. 2021 Restricted Stock Unit Award Plan (the "Plan").
- 2. Par value of \$.01 must be paid by Reporting Person upon exchange of Restricted Stock Units for stock.
- 3. 100% of Restricted Stock Units vest on December 31, 2022 or earlier if Reporting Person's service as an employee of Issuer is terminated by Issuer without Cause (as defined in the Plan) or due to Reporting Person's death or Disability (as defined in the Plan) or a qualifying change of control occurs. Distributions in respect of vested Restricted Stock Units will be made in three equal installments on the first business day of each of January 2024, 2025, and 2026 or earlier upon a qualifying change of control which also meets certain criteria of Section 409A of the Internal Revenue Code.
- 4. Not Applicable.

/s/ Albert W. Brzeczko

03/16/2022

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.